Managing multiple myeloma in the elderly: Are we making progress?

Expert Review of Hematology

Volumn 4, Issue 3, 2011, Pages 301-315

  Quach, Hang ^a,b,c,d   Prince, H Miles ^a,d,e   Spencer, Andrew ^a,c  

^a MONASH UNIVERSITY   (Australia)

^b MONASH MEDICAL CENTRE   (Australia)

^c Malignant Hematology and Stem Cell Transplantation   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

elderly; multiple myeloma; progress

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; LENALIDOMIDE; MELPHALAN; PREDNISONE; THALIDOMIDE;

AGED; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; ELDERLY CARE; HUMAN; MAINTENANCE THERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PRIORITY JOURNAL; REVIEW; SALVAGE THERAPY;

AGED; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; MULTIPLE MYELOMA; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS;

EID: 79959218180     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/ehm.11.18     Document Type: Review

References (104)

1. Kumar SK, Rajkumar SV, Dispenzieri A et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 111(5), 2516-2520 (2008)
2. Barlogie B, PinedαRoman M, van Rhee F et al. Thalidomide arm of total therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood 112(8), 3115-3121 (2008)
3. Brenner H, Gondos A, Pulte D. Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010. Haematologica 94(2), 270-275 (2009)
4. Clavio M, Casciaro S, Gatti AM et al. Multiple myeloma in the elderly: clinical features and response to treatment in 113 patients. Haematologica 81(3), 238-344 (1996)
5. Froom P, Quitt M, Aghai E. Multiple myeloma in the geriatric patient. Cancer 66(5), 965-967 (1990)
6. Harousseau JL, Palumbo A, Richardson PG et al. Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the Phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. Blood 116(19), 3743-3750 (2010)
7. Chanan-Khan AA, Giralt S. Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J. Clin. Oncol. 28(15), 2612-2624 (2010)
8. Spencer A. No longer the poor relations. Blood 116(19), 3685-3686 (2010)
9. Landgren O, Weiss BM. Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis. Leukemia 23(10), 1691-1697 (2009)
10. Turesson I, Velez R, Kristinsson SY, Landgren O. Patterns of multiple myeloma during the past 5 decades: stable incidence rates for all age groups in the population but rapidly changing age distribution in the clinic. Mayo Clinic Proc. 85(3), 225-230 (2010)
11. Devesa SS, Silverman DT. Cancer incidence and mortality trends in the United States: 1935-74. J. Natl Cancer Inst. 60(3), 545-571 (1978)
12. Velez R, Beral V, Cuzick J. Increasing trends of multiple myeloma mortality in England and Wales; 1950-79, are the changes real? J. Natl Cancer Inst. 69(2), 387-392 (1982)
13. Levi F, Lucchini F, Negri E, Boyle P, La Vecchia C. Cancer mortality in Europe, 1995-1999, and an overview of trends since 1960. Int. J. Cancer 110(2), 155-169 (2004)
14. Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N. Engl. J. Med. 335(2), 91-97 (1996)
15. Child JA, Morgan GJ, Davies FE et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N. Engl. J. Med. 348(19), 1875-1883 (2003)
16. Anagnostopoulos A, Gika D, Symeonidis A et al. Multiple myeloma in elderly patients: prognostic factors and outcome. Eur. J. Hematol. 75(5), 370-375 (2005).
17. Kristinsson SY, Landgren O, Dickman PW, Derolf AR, Bjorkholm M. Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J. Clin. Oncol. 25(15), 1993-1999 (2007)
18. San Miguel JF, Schlag R, Khuageva NK et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N. Engl. J. Med. 359(9), 906-917 (2008)
19. Palumbo A, Bringhen S, Liberati AM et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood 112(8), 3107-3114 (2008)
20. Rodon P, Linassier C, Gauvain JB et al. Multiple myeloma in elderly patients: presenting features and outcome. Eur. J. Hematol. 66(1), 11-17 (2001)
21. Quach H, Prince HM, Mileshkin L. Treatment strategies in elderly patients with multiple myeloma: current status. Drugs Aging 24(10), 829-850 (2007)
22. Palumbo A, Triolo S, Baldini L et al. Dose-intensive melphalan with stem cell support (CM regimen) is effective and well tolerated in elderly myeloma patients. Haematologica 85(5), 508-513 (2000)
23. Badros A, Barlogie B, Siegel E et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br. J. Hematol. 114(3), 600-607 (2001)
24. Richardson PG, Sonneveld P, Schuster MW et al. Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. Br. J. Hematol. 137(5), 429-435 (2007)
25. Blade J, Lopez-Guillermo A, Bosch F et al. Impact of response to treatment on survival in multiple myeloma: results in a series of 243 patients. Br. J. Hematol. 88(1), 117-121 (1994)
26. Oivanen TM, Kellokumpu-Lehtinen P, Koivisto AM, Koivunen E, Palva I. Response level and survival after conventional chemotherapy for multiple myeloma: a Finnish Leukaemia Group study. Eur. J. Hematol. 62(2), 109-116 (1999)
27. Blade J, Samson D, Reece D et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br. J. Hematol. 102(5), 1115-1123 (1998)
28. Durie BG, Harousseau JL, Miguel JS et al. International uniform response criteria for multiple myeloma. Leukemia 20(12), 2220 (2006)
29. Barlogie B, Jagannath S, Vesole DH et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 89(3), 789-793 (1997)
30. Davies FE, Forsyth PD, Rawstron AC et al. The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma. Br. J. Hematol. 112(3), 814-819 (2001)
31. Alexanian R, Weber D, Giralt S et al. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant. 27(10), 1037-1043 (2001)
32. Mateos MV, Oriol A, Martinez-Lopez J et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol. 11(10), 934-941 (2010)
33. Palumbo A, Bringhen S, Rossi D et al. Bortezomib-melphalan-prednisone- thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J. Clin. Oncol. 28(34), 5101-5109 (2010)
34. Niesvizky R, Richardson PG, Rajkumar SV et al. The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, Phase 3 APEX trial in relapsed multiple myeloma. Br. J. Hematol. 143(1), 46-53 (2008)
35. Harousseau J, Weber D, Dimopoulos M et al. Relapsed/refractory multiple myeloma patients treated with lenalidomide/dexamethasone who achieve a complete or near complete response have longer overall survival and time to progression compared with patients achieving a partial response. Blood 110, 3598 (2007) (Abstract)
36. Quach H, Mileshkin L, Seymour JF et al. Predicting durable remissions following thalidomide therapy for relapsed myeloma. Leuk. Lymph. 50(2), 223-229 (2009)
37. van de Velde HJ, Liu X, Chen G, Cakana A, Deraedt W, Bayssas M. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica 92(10), 1399-1406 (2007)
38. Palumbo A, Bringhen S, Caravita T et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367(9513), 825-831 (2006)
39. Facon T, Mary JY, Hulin C et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06), a randomised trial. Lancet 370(9594), 1209-1218 (2007)
40. Gay F, Larocca A, Wijermans P et al. Complete response correlates with long-term progression-free and overall survivals in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood 117(11), 3025-3031 (2011)
41. Ludwig H, Hajek R, Tothova E et al. Thalidomide-dexamethasone compared to melphalan-prednisolone in elderly patients with multiple myeloma. Blood 113(15), 3435-3442 (2009)
42. PinedαRoman M, Bolejack V, Arzoumanian V et al. Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease. Br. J. Hematol. 136(3), 393-399 (2007)
43. Zhan F, Barlogie B, Arzoumanian V et al. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood 109(4), 1692-1700 (2007).
44. Harousseau JL, Avet-Loiseau H, Attal M et al. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 trials. J. Clin. Oncol. 27(34), 5720-5726 (2009)
45. Jantunen E. Autologous stem cell transplantation beyond 60 years of age. Bone Marrow Transplant. 38(11), 715-720 (2006)
46. Mehta J, Singhal S. High-dose chemotherapy and autologous hematopoietic stem cell transplantation in myeloma patients under the age of 65 years. Bone Marrow Transplant. 40(12), 1101-1114 (2007)
47. Sirohi B, Powles R, Treleaven J et al. The role of autologous transplantation in patients with multiple myeloma aged 65 years and over. Bone Marrow Transplant. 25(5), 533-539 (2000)
48. Palumbo A, Triolo S, Argentino C et al. Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients. Blood 94(4), 1248-1253 (1999)
49. Spencer A, Seldon M, Deveridge S et al. Induction with oral chemotherapy (CID) followed by early autologous stem cell transplantation for de novo multiple myeloma patients. Hematol. J. 5(3), 216-221 (2004)
50. Wu P, Davies FE, Horton C et al. The combination of cyclophosphomide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide- vincristine-doxorubicin- methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: a case-matched analysis. Leuk. Lymph. 47(11), 2335-2338 (2006)
51. Kyriakou C, Thomson K, D Sa S et al. Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma. Br. J. Hematol. 129(6), 763-770 (2005)
52. Harousseau JL, Attal M, Avet-Loiseau H et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 Phase III trial. J. Clin. Oncol. 28(30), 4621-4629 (2010)
53. Popat R, Oakervee HE, Hallam S et al. Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up. Br. J. Hematol. 141(4), 512-516 (2008)
54. Morgan GJ, Schey SA, Wu P et al. Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients. Br. J. Hematol. 137(3), 268-269 (2007)
55. Rajkumar SV, Jacobus S, Callander NS et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 11(1), 29-37 (2010)
56. Wang M, Delasalle K, Giralt S, Alexanian R. Rapid control of previously untreated multiple myeloma with bortezomib-lenalidomide-dexamethasone (BLD)Hematology 15(2), 70-73 (2010)
57. Richardson PG, Weller E, Lonial S et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 116(5), 679-686 (2010)
58. Dingli D, Pacheco JM, Nowakowski GS et al. Relationship between depth of response and outcome in multiple myeloma. J. Clin. Oncol. 25(31), 4933-4937 (2007)
59. Dingli D, Gay F, Buadi F, Dispenzieri A, Gertz M. Depth of response with stem cell transplantation and outcome for multiple myeloma in the era of novel agents. Blood 114, 506 (2009) (Abstract 1228)
60. Waage A, Gimsing P, Fayers P et al. Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood 116(9), 1405-1412 (2010)
61. Hulin C, Facon T, Rodon P et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J. Clin. Oncol. 27(22), 3664-3670 (2009)
62. Beksac M, Haznedar R, Firatli-Tuglular T et al. Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group. Eur. J. Hematol. 86(1), 16-22 (2011)
63. Kapoor P, Rajkumar SV, Dispenzieri A et al. Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a metαanalysis. Leukemia 25(4), 689-696 (2011)
64. Bringhen S, Larocca A, Rossi D et al. Efficacy and safety of once weekly bortezomib in multiple myeloma patients. Blood 116(23), 4745-4753 (2010)
65. Palumbo A, Delforge M, Catalano J, Hajek R, Dimopoulos M. A Phase 3 study evaluating the efficacy and safety of lenalidomide combined with melphalan and prednisone in patients ≥65 years with newly diagnosed multiple myeloma (NDMM), continous use of lenalidomide vs. fixed-duration regimens. Blood 116, 662 (2010)
66. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J. Clin. Oncol. 24(3), 431-436 (2006)
67. Cavo M, Zamagni E, Tosi P et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 106(1), 35-39 (2005)
68. Gay F, Hayman SR, Lacy MQ et al. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood 115(7), 1343-1350 (2010)
69. Hicks LK, Haynes AE, Reece DE et al. A metαanalysis and systematic review of thalidomide for patients with previously untreated multiple myeloma. Cancer Treatment Rev. 34(5), 442-452 (2008)
70. Spencer A, Prince HM, Roberts AW et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J. Clin. Oncol. 27(11), 1788-1793 (2009)
71. Attal M, Harousseau JL, Leyvraz S et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 108(10), 3289-3294 (2006)
72. Lokhorst HM, van der Holt B, Zweegman S et al. A randomized Phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood 115(6), 1113-1120 (2010)
73. Barlogie B, Tricot G, Anaissie E et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N. Engl. J. Med. 354(10), 1021-1030 (2006)
74. Feyler S, Rawstron A, Jackson G, Snowden JA, Cocks K, Johnson RJ. Thalidomide maintenance following high-dose therapy in multiple myeloma: a UK myeloma forum Phase 2 study. Br. J. Hematol. 139(3), 429-433 (2007)
75. McCarthy P, Owzar K, Stadtmauer E, Giralt S, Anderson KC. Phase III intergroup study of lenalidomide (CC-5013) versus placebo maintenace therapy following single autologous stem cell transplant for multiple myeloma (CALBG 100104), initial report of patient accrual and averse events. Blood 114, 3416a (2009)
76. Sahebi F, Krishnan A, Forman S. High rate of complete remission (CR) and upgraded response with weekly maintenance bortezomib post single autologous peripheral stem cell transplant (PSCT) in patients with multiple myeloma. Results of a Phase II prospective study. Blood 116 (2010) (Abstract 2399)
77. Offidani M, Corvatta L, Polloni C et al. Thalidomide-dexamethasone versus interferon-αdexamethasone as maintenance treatment after ThaDD induction for multiple myeloma: a prospective, multicentre, randomised study. Br. J. Hematol. 144(5), 653-659 (2009)
78. Palumbo A, Dimopoulos M, Delforge M, Kropff M, Foa R, Catalano J. A Phase III study to determine the efficacy and safety of lenalidomide in combination with melphalan and prednisolone (mpr) in elderly patients with newly diagnosed multiple myeloma. Blood 114 (2009) (Abstract 613a)
79. Palumbo A, Ambrosini MT, Benevolo G et al. Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood 109(7), 2767-2772 (2007)
80. Anagnostopoulos A, Weber D, Rankin K, Delasalle K, Alexanian R. Thalidomide and dexamethasone for resistant multiple myeloma. Br. J. Hematol. 121(5), 768-771 (2003)
81. Offidani M, Bringhen S, Corvatta L et al. Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma. Eur. J. Hematol. 78(4), 297-302 (2007)
82. Kropff M, Bisping G, Schuck E et al. Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Br. J. Hematol. 138(3), 330-337 (2007)
83. Knop S, Gerecke C, Liebisch P et al. Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom)Blood 113(18), 4137-4143 (2009)
84. Weber DM, Chen C, Niesvizky R et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N. Engl. J. Med. 357(21), 2133-2142 (2007)
85. Dimopoulos M, Spencer A, Attal M et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N. Engl. J. Med. 357(21), 2123-2132 (2007)
86. Stadtmauer EA, Weber DM, Niesvizky R et al. Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma. Eur. J. Hematol. 82(6), 426-432 (2009)
87. Vogl DT, Stadtmauer EA, Richardson PG et al. Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma. Br. J. Hematol. 147(4), 531-534 (2009)
88. Richardson PG, Sonneveld P, Schuster MW et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the Phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br. J. Hematol. 144(6), 895-903 (2009)
89. Dimopoulos MA, Mateos MV, Richardson PG et al. Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan- prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the Phase 3 VISTA study. Eur. J. Hematol. 86(1), 23-31 (2011)
90. Lenhard RE Jr, Oken MM, Barnes JM, Humphrey RL, Glick JH, Silverstein MN. High-dose cyclophosphamide. An effective treatment for advanced refractory multiple myeloma. Cancer 53(7), 1456-1460 (1984)
91. Sonneveld P, van der Holt B, Segeren CM et al. Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial. Haematologica 92(7), 928-935 (2007)
92. Dammacco F, Castoldi G, Rodjer S. Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br. J. Hematol. 113(1), 172-179 (2001)
93. Palumbo A, Rajkumar SV, Dimopoulos MA et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22(2), 414-423 (2008)
94. Vickrey E, Allen S, Mehta J, Singhal S. Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy. Cancer 115(1), 229-232 (2009)
95. Quach H, Fernyhough L, Henderson R, Corbett G, Lynch K, Prince HM. Lower-dose lenalidomide and dexamethasone reduces toxicity without compromising efficacy in patients with relapse/refractory myeloma, who are aged ≥60 years or have renal impairment: planned interim results of a prospective multicentre Phase II trial. Blood 116 (2010) (Abstract 1961)
96. Siegel DS, Desikan KR, Mehta J et al. Age is not a prognostic variable with autotransplants for multiple myeloma. Blood 93(1), 51-54 (1999)
97. Fermand JP, Katsahian S, Divine M et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J. Clin. Oncol. 23(36), 9227-9233 (2005)
98. Niesvizky R, Ely S, Mark T et al. Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer 117(2), 336-342 (2011).
99. Kaiser M, Lamottke B, Mieth M et al. Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma. Eur. J. Hematol. 84(4), 337-344 (2010)
100. Ocio EM, Vilanova D, Atadja P et al. In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. Haematologica 95(5), 794-803 (2010)
101. Sanchez E, Shen J, Steinberg J et al. The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo. Leuk. Res. 35(3), 373-379 (2010)
102. Richardson PG, Mitsiades CS, Laubach JP, Lonial S, Chanan-Khan AA, Anderson KC. Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers. Br. J. Hematol. 152(4), 367-379 (2011)
103. Allegra A, Sant antonio E, Penna G et al. Novel therapeutic strategies in multiple myeloma: role of the heat shock protein inhibitors. Eur. J. Hematol. 86(2), 93-110 (2011)
104. Wijermans P, Schaafsma M, Termorshuizen F et al. Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. J. Clin. Oncol. 28(19), 3160-3166 (2010).